Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
COMPOSITION — All influenza vaccines available in the US this season are quadrivalent; they contain two influenza A and two influenza B virus antigens (see Table 1). Influenza A viruses are the main cause...
ISSUE
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be approved by the FDA for this indication. It was previously approved for treatment of atopic dermatitis.1
NONSEGMENTAL VITILIGO ― In patients with vitiligo, destruction of melanocytes …